Who We Are

Founded in 2016, TrueBinding Inc. is a pioneering clinical-stage biotherapeutic company dedicated to developing transformative treatments for patients with serious and underserved medical conditions. We focus on neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Autism Spectrum, as well as stroke, metabolic disorders, oncology, and other areas with significant unmet medical need.

At the heart of our innovation is the TrueBinding™ platform, a proprietary, cutting-edge technology that powers our drug discovery and development efforts. Leveraging this platform, we have successfully identified and validated over six novel drug targets, leading to the development of potentially game-changing monoclonal antibody therapeutics. With these advances, TrueBinding is emerging as a leader in the biopharmaceutical industry—bringing hope to patients, caregivers, and the broader medical community.

In 2023, TrueBinding obtained FDA approval for an Expanded Access Program (EAP) under an Intermediate-Size Protocol, the only one of its kind approved that year. This program was renewed in 2024 and 2025, reinforcing our commitment to providing early access to promising investigational therapies for patients with urgent, unmet needs.

Beyond therapeutic development, TrueBinding also offers contract development and manufacturing (CDMO) services. Our experienced team and state-of-the-art facilities enable biopharmaceutical partners to accelerate the development and production of monoclonal antibodies with unmatched efficiency and precision.

With a bold vision and a strong scientific foundation, TrueBinding is committed to changing the future of medicine—one breakthrough at a time.